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Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology,
manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease-modifying therapies
are unavailable. Activation of microglia and production of toxic cytokines suggest a role of neuroinflammation in
MSA pathogenesis. This pilot clinical trial evaluated safety and tolerability of intravenous immunoglobulin (IVIG)
in MSA.
Methods: This was a single-arm interventional, single-center, open-label pilot study. Interventions included monthly
infusions of the IVIG preparation PrivigenW, dose 0.4 gram/kg, for 6 months. Primary outcome measures evaluated
safety and secondary outcome measures evaluated preliminary efficacy of IVIG. Unified MSA Rating Scale (UMSARS)
was measured monthly. Quantitative brain imaging using 3T MRI was performed before and after treatment.
Results: Nine subjects were enrolled, and seven (2 women and 5 men, age range 55–64 years) completed the
protocol. There were no serious adverse events. Systolic blood pressure increased during IVIG infusions (p<0.05).
Two participants dropped out from the study because of a non-threatening skin rash. The UMSARS-I (activities of
daily living) and USMARS-II (motor functions) improved significantly post-treatment. UMSARS-I improved in all
subjects (pre-treatment 23.9 ± 6.0 vs. post-treatment 19.0±5.9 (p=0.01). UMSARS-II improved in 5 subjects, was
unchanged in 1 and worsened in 1 (pre-treatment 26.1±7.5 vs. post-treatment 23.3±7.3 (p=0.025). The MR imaging
results were not different comparing pre- to post-treatment.
Conclusions: Treatment with IVIG appears to be safe, feasible and well tolerated and may improve functionality in
MSA. A larger, placebo-controlled study is needed.Background
Multiple system atrophy (MSA) is a sporadic late-onset
progressive neurodegenerative disorder [1]. The preva-
lence of MSA is 1.9 to 4.9 in 100,000 people [2,3]. MSA
predominantly affects the central nervous system and
results in a combination of parkinsonism, cerebellar syn-
drome, and dysautonomia with orthostatic hypotension.
The disease progresses relatively rapidly with a mean
survival of 6 to 9 years. Pharmacological management
remains limited, and at present, there are no therapies
that modify disease progression [4].
MSA is predominantly a white matter disease that is
associated with widespread myelin degeneration and sec-
ondary neuronal loss [5]. The neuropathological hallmark* Correspondence: novakp@ummhc.org
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reproduction in any medium, provided the orof MSA is the presence of oligodendroglial cytoplasmic
inclusions [6] (glial cytoplasmic inclusions) staining posi-
tively for α–synuclein [7]. Additional feature of MSA is
aggregation of the filamentous α–synuclein in the neurons
in several brain regions. It is believed that α–synuclein
play a major role in MSA since α–synuclein aggregation
occurs in the oligodendroglia and neurons in its early
stages [8].
The cause of MSA remains unknown. Several lines of
evidence suggest that inflammation could contribute to
neurodegeneration in MSA [9-11]. Microglia are the pri-
mary immune effector cells in the brain. Activated micro-
glia can mediate the tissue injury through secretion of
toxic cytokines, complement proteins, and free radicals
that can lead to the degeneration of myelin, axonal
dysfunction, and neuronal death. Activation of microglia
[9-11] and upregulation of several inflammatory genes
[12] have been described in patients with MSA.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inflammatory properties with multiple mechanisms of
action. IVIG inhibits autoreactive T cells, suppresses
autoantibodies through anti-idiotypic interactions and
interferes with the production of cytokines [13]. IVIG is
effective in the treatment of several autoimmune or neu-
roinflammatory disorders.
This pilot clinical trial was based on the hypothesis
that the neuroinflammatory activity in MSA can be
altered by using IVIG. Preliminary results were pre-
sented in abstract form [14].
Methods
Participants
This was a single-arm, interventional-, single-center,
open-label prospective study. Patients with a history of
probable MSA [15] were enrolled in the study (Table 1).
All patients had some combination of cerebellar syn-
drome and parkinsonism, poorly responding to levo-
dopa; autonomic failure, wherein systolic blood pressure
dropped ≥ 30 mm Hg within 3 minutes of standing, and
urinary incontinence. Cerebellar findings included at
least one of the following: ataxic gait, cerebellar dysarth-
ria, cerebellar oculomotor findings or limb ataxia. To
minimize the chance of enrollment of non-MSA
patients, the presence of all three syndromes (auto-
nomic, parkinsonism, and cerebellar) was required even
though, in the consensus criteria for probable MSA,
concurrent occurrence of both parkinsonism and cere-
bellar syndrome is not required for diagnosis [15,16].
Brain MRI was performed in all subjects to rule out
structural abnormalities that can mimic MSA. Add-
itional exclusion criteria included the presence of de-
mentia and volume depletion.
The severity and progression of the disease was evalu-
ated by the Unified MSA Rating Scale (UMSARS), a vali-
dated and disease-specific instrument [17]. UMSARS
part I (UMSARS-I) evaluates activities of daily living,
part II (UMSARS-II) evaluates motor functions, part III
(UMSARS-III) evaluates autonomic functions, and part
IV (UMSARS-IV) evaluates disability. Blood pressure
measurements of UMSARS-III were obtainedTable 1 Characteristics of subjects
Age in years (median, range) 59, 55-64
Gender (women/men) 2/5
Disease duration (median, range) 5, 2-14
MSA Type (cerebellar/parkinsonian) 5/2
Levodopa (number of patients) 3
Amantadine (number of patients) 3
Proamatine (number of patients) 3
Fludrocortisone (number of patients) 2
Pyridostigmine (number of patients) 2automatically with the use of Dinamap ProCare Monitor
100 (GE, Fairfield, CT).Imaging
Anatomical images were acquired on a 3T GE HDX
MRI scanner using three-dimensional magnetization
prepared rapid gradient echo (MP-RAGE) images to
quantify volumes of white and gray matter in the ana-
tomical regions of interest. MP-RAGE images of individ-
ual participant were co-registered, and then registered to
the standard anatomical template using the Statistical
Parametric Mapping software package (SPM, Wellcome
Department of Imaging Neuroscience, University Col-
lege, London, UK) [18,19]. MR findings were compared
to 37 age and gender matched healthy controls that par-
ticipated in the same imaging protocol. We calculated
volumes in the frontal, parietal, temporal, occipital, and
cerebellar regions and their respective subregions.
Details of segmentation and data processing were pub-
lished previously [20].Interventions
We used PrivigenW [21], a commercial preparation that
is a high-purity 10% liquid IVIG stabilized by L-prolin.
PrivigenW retains the Fc and Fab functions of the im-
munoglobulin G (IgG) molecule since heating and the
chemical or enzymatic treatment of the preparation are
avoided. The median half-life of PrivigenW is 36.6 days.
Interventions included monthly infusions of PrivigenW
with the dose being equal to 0.4 gram of the preparation
per kilogram of body weight, for 6 months. This dose is
recommended for treatment of primary humoral im-
munodeficiency [21,22]. The dose remained unchanged
on gram per kg basis but did change proportionally with
body weight changes during the study. Premedication
was not routinely administered. Premedication including
acetaminophen, antihistamines, and oral prednisone was
permitted only patients experienced an infusion related
adverse event (AE).
Outcome measures: The primary outcome measure
was to evaluate the safety and tolerability of the IVIG
infusions in patients with MSA. The primary endpoint
was defined as the frequency of AEs. AEs including their
severity and relationship to the IVIG were assessed
throughout the study and at least 60 days after the last
infusion. The AEs were considered to be related to the
IVIG infusion (infusional AE) if they occurred during an
infusion or within 72 hours afterwards. Non-infusional
AEs were further classified as possible related to IVIG or
likely not related to IVIG. The safety and tolerability end
points using IVIG are unknown for MSA. For the pri-
mary immunodeficiency diseases, the FDA recommends
the cutoff limit 40% for all AEs [23].
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preliminary efficacy of IVIG for the treatment of MSA.
The primary efficacy endpoint was change of the
UMSARS ratings compared to baseline. The secondary
efficacy end points were changes of quantitative volu-
metric imaging also compared to a baseline.Protocol
The experimental protocol included a screening visit, 6
infusion visits a month apart, and a final visit. Creatinine
and blood urea nitrogen were obtained at each visit to
assess kidney function and hydration status. The levels
of IgA were also obtained at the screening to rule out
IgA deficiency since PrivigenW contains IgA in trace
amounts. CRP was obtained at the screening and final
visit. The UMSARS ratings were obtained at each visit
before infusions. Imaging was done on the same day or
within few days after the screening visit and within one
month after last infusion. The approved protocol for
IVIG infusions at the University of Massachusetts Med-
ical School was based on manufacturer’s recommenda-
tions [21]. For each infusion adverse events were
documented during the infusion and by follow up inter-
view 3 days later.
Subject received IVIG by infusion pump. Infusions
began at the rate of 0.5 mg/kg/min for 15 minutes in sit-
ting or semi recumbent position. All subjects were
closely supervised. The subject’s vital signs (heart rate,
respiratory frequency, blood pressure, and temperature)
were measured before the infusion, than twice in 15-
minute intervals, then again every 30 minutes until the
end of the infusion. The infusion rate was gradually
increased each time vital signs were measured until the
maximum rate of 4 mg/kg/min was achieved. If signifi-
cant changes in vital signs occurred the infusion rates
were usually slowed down or kept the same until the
vital signs were again stable.Statistical analysis
One-way ANOVA for repeated measures test was used
to compare the difference between analyzed variables
obtained at baseline, during treatment, and after treat-
ment. All statistical analysis was done using JMP 8.0
(SAS Institute, Inc., NC).Standard protocol approvals, registrations, and
patient consents
The study was approved by the Institutional Review
Board of the University of Massachusetts Medical School
and the Institutional Review Board of the Beth Israel
Deaconess Medical Center, where MR imaging was per-
formed. All subjects signed informed consent forms.Results
Twelve subjects were screened, three subjects failed
to meet the inclusion criteria, nine participants
were enrolled in the study, and seven completed the
protocol. Demographic characteristics and medications
are in the Table 1. The disease duration was calculated
from the onset of the first symptoms, which proceeded
the time of diagnosis. IgA deficiency was ruled out in all
subjects.
Medications
There have been some changes in medications in spite
of efforts not to change any medication for the trial dur-
ation. Subject #4 discontinued proamatine and fludro-
cortizone because of subjective improvement. Subject #3
discontinued levodopa because of questionable efficacy.
The neurologist treating subject # 2 increased the dose
of ropinirole because of worsening of parkinsonism.
Adverse Events
There were 42 IVIG infusions. No serious AEs were
observed and most of subjects tolerated the treatment
protocol well.
Safety
Table 2 summarizes the frequency of non-serious ad-
verse symptoms observed for all infusions. There were
43 infusional AEs. However, excluding BP-related infu-
sional AEs, there were 11 infusional AEs (frequency of
occurrence 26.2%). There were additional 18 AEs that
occurred beyond 72 hour limit (frequency of occurrence
42.8%). The most common infusional AE was an imme-
diate and transient elevation of the systemic blood pres-
sure (BP). 100% subjects (occurrence 33 times out of 42
infusions) experienced an increase of systolic BP ≥ 20
and diastolic BP ≥10 mg Hg at least once. The BP eleva-
tion usually occurred within minutes of the infusion
onset, necessitating a reduction in the infusion rate,
changes of position more upright, interruption of infu-
sion and/or allowing the patient to void. ANOVA showed
a significant increase in systolic BP (p=0.05, mean±sd sys-
tolic BP 129.1±32.4 mmHg before infusions, 159.0±25.8
mm Hg highest systolic BP during infusions), but the in-
crease in diastolic BP was not significant (p=0.20, diastolic
BP 79.1±16.5 mmHg before infusions, 88.6±13.8 mm Hg
highest diastolic BP during infusions). Skin rash was the
second most common AE. Two subjects withdrew from
the study because they experienced a skin rash during or
immediately (minutes) after IVIG infusions.
Functional measure
UMSARS-I was improved in all 7 subjects (Figure 1)
(p<0.01). UMSARS-II improved in 5 subjects (p<0.025),
was unchanged in 1 subject and was worse by 1 point in
Table 2 Characterizations of adverse events
Type No Subjects R Comments
1 Elevated BP 7 7 I Transient, responding to adjusting the infusion rate
2 Accidental injury 1 1 N After It4, nose fracture
3 UTI 1 1 N After It5, treated with antibiotics
4 Pruritic skin rash 4 3 I 2 subjects withdrew from the study. In these subjects, one subject experienced rash after
It1 and second after It2. 1 subject experienced rash after I4 and I5 and was treated with
Diphenhydramine, Acetaminophen and oral Prednisone
5 Increased temperature
and/or skin flushing
5 1 I Treated with Diphenhydramine, Acetaminophen, and slowing the infusion rate
6 RLS 1 1 N Diagnosed after It4, treated with iron supplements
8 Decreased GFR 1 2 N After It5 and It6, resolved
9 Ankle edema 1 N After It5, treated with diazide diuretics
10 Elevated BUN 1 1 N After It5, started trial with elevated BUN at screening visit, resolved
11 Worsening of allergies 2 1 N Worsening of running nose and cough after It5 and It6, also associated with cold and fever
after It6, treated with Acetaminophen, Pseudoephedrine, and Diphenhydramine.
13 Nodular lung abnormality 1 1 N Later determined to be abnormal tangle of veins, probably since birth
14 Low potassium 1 1 P After It1, treated with increased dose of potassium
15 GI viral infection 1 1 N After It5, treated with fluids, antiemetics and anti-diarrheal agents
16 Elevated PSA 1 1 N Before It1, resolved
17 Wrist strain 1 1 N After It1, resolved
18 Worsening of sleep apnea 1 1 N After It2, prrescribed CPAP
Legends: UTI=urinary tract infection, BUN=blood urea nitrogen, GFR=glomerular filtration rate, PSA=prostate specific antigen, CPAP=continuous positive airway
pressure. R= relationship of the AE to the study drug, N= not related, PR=possibly related, I=infusional AE. It1-6 designates the infusion treatment 1–6.
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before the final visit. Comparison of the final-visit and
the baseline-visit ratings shows a significant decrease in
UMSARS-I (p=0.0128) and UMSARS-II (p=0.025). The
differences in UMSARS-III (systolic BP p=0.67, diastolic
BP p=0.45) and UMSARS-IV (p=0.36) were not signifi-
cant. C-reactive protein levels did not change with treat-
ment (p=0.25).
Imaging did not show differences in gray and white
matter volumes in post treatment MSA subjects. As
compared to controls, MSA subjects had lower gray
matter volume (p<0.05) in cerebellum, putamen and
hippocampus bilaterally. White matter volume was
increased (p<0.05) in the frontal lobe bilaterally, right
parietal lobe, right superior temporal gyrus, left middle
temporal gurus, cerebellum and putamen bilaterally.
There were no significant differences in volumes com-
pared before and after interventions.
Discussion
This pilot open label study investigated the safety and
preliminary efficacy of using IVIG over a 6-month
period for treatment of MSA. IVIG treatment was
well tolerated. Post-treatment functional assessment
showed promising improvement of many areas of
daily living activities. IVIG infusions were acutely
associated with increase in blood pressure, but post-treatment orthostatic hypotension did not change
significantly. Imaging studies have shown brain and
cerebellar atrophy.
No serious AEs occurred as a result of the total 42
IVIG infusions. Previously reported AEs associated with
IVIG, such as renal failure and thromboembolic events,
did not occur in our cohort. Minor AEs are common
with IVIG treatment and range from 2% to 25% per in-
fusion [24,25]. The most commonly reported AE’-
associated with PrivigenW is headache, which occurs in
65% of patients [21]. No headaches were observed in our
group. Skin reaction occurs rarely with IVIG. In our
study two subjects developed pruritic rash and they
withdrew for safety reasons. It is likely that rash in one
subject was not related to IVIG because it persisted be-
yond 3 months after the last infusion, and then it was
reassociated with a food allergy. The most common AE
in our study was elevated BP, which occurred in all of
the subjects. This appears to be an MSA-specific effect
of IVIG or PrivigenW since, to our knowledge, this is the
first study reporting transient elevation of the BP due
PrivigenW infusions. Previous studies utilizing PrivigenW
observed infusion induced hypotensive reactions [24-26].
However a transient BP elevation was reported with
other IVIG preparations. In our cohort, elevated BP
declined when the infusion rate was slowed down, or
position changed from supine to semi recumbent or
Figure 1 Average UMSARS scores. Each dot represents an average
score at each visit. The bars represent standard deviations.
A=UMSARS part I scores, B=UMSARS part II scores.
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effective maneuver to reduce BP.
The mechanisms leading to IVIG-induced BP eleva-
tion are unclear. BP changes were typically observed
minutes after starting infusions rendering the effect of
volume expansion unlikely. It also is unlikely that
sensitization to IVIG plays a role in BP elevation because
BP elevation occurred during the first infusion in six of
seven participants. Possible mechanisms include the ef-
fect of a yet-to-be-determined substance in IVIG or a
specific substance in PrivigenW. Possible candidates are
cytokines, vasoactive substances or other proteins, or L-
prolin that is unique to PrivigenW. MSA patients can
have denervation hypersensitivity that can render them
more sensitive to vasoactive substances in PrivigenW. It
is of interest to elucidate PrivigenW-induced mechanisms
of BP elevation given that, in general, treatment of
hypotension in MSA can be difficult.CRP as a marker of systemic inflammation did not
change significantly following IVIG treatment. The main
reason why the expected reduction of CRP was not
observed in our trial was the fact that two subjects
experienced viral infection at the final visit that
increased CRP dramatically. Without these 2 subjects,
the mean CRP would be reduced at the end of the trial
compared to baseline.
Because a biomarker of MSA is not available, the
UMSARS was chosen as a proxy for the disease stage.
At present, UMSARS is the best instrument for evalu-
ation of disease severity and disease progression [16].
Baseline UMSARS scores in our study are similar to
those of a progressive observational study by the North
American MSA Group of 67 patients [27]. In that study
the average increases of the UMSARS score for part I
and part II were equal to 3.1 and 4.5 points over 12
months. However, the European MSA study group [28]
showed a faster progression of MSA as indicated by the
increase in UMSARS-I by 6.7 points and UMSARS-II by
9.6 points over 12 months. In our study, group averages
showed decreases in the part I and part II scores. These
results are encouraging, given that current therapies for
MSA are only symptomatic.
This pilot trial was open label and therefore a placebo
effect cannot be ruled out. Investigators who evaluated
the UMSARS (PN, PR) were not blinded to the interven-
tion, and so the rating could be biased. Only a larger
placebo-controlled double-blinded study can effectively
delineate the role of IVIG in the treatment of MSA.
However, PrivigenW appears to have a profound immedi-
ate effect on BP, as discussed above. This fact can com-
plicate the blinding of future studies since BP responses
to infusions can distinguish the interventions from pla-
cebo. On the other hand, there was no significant differ-
ence in systemic BP on UMSARS-III based on a
comparison of screening rating and the final visit rating
suggesting that hypertensive effect of PrivigenW is transi-
ent and therefore theoretically should not “mask” the
putative disease-modifying effect. This fact is important
to consider since what appears to be a slowing of disease
progression could be due to symptomatic drug affect.
The effect of IVIG on MSA remains to be clarified. The
present study design was based on the assumption that
brain inflammation contributes to MSA. Furthermore,
IVIG enters the central nervous system only if the blood
brain barrier (BBB) is disrupted [29]. Although measure-
ment of the extravasation of IVIG was never performed in
MSA, BBB is impaired in MSA [30,31] including at basal
ganglia and at similar areas that show activation of micro-
glia [32]. However, it is not clear whether the disruption of
blood brain barrier is necessary for IVIG to be effective
with MSA. Alternatively, IVIG could exhibit its effect on
systemic modulation of the immune system.
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differences in particular brain areas of MSA subjects as
compared with controls. Our results are similar to those
of previous studies [33-35]. Our MSA patients had
reduced gray matter volume mainly in cerebellum and
putamen and increased in hippocampus. White matter
volume was increased in frontal lobe, putamen, cerebel-
lum and hippocampus. The significance of the increase
of the white matter remains unclear. It may simply re-
flect that proportionally more gray matter was lost than
true enlargement of the white matter.
We also compared volumes before and after the treat-
ment 8 months apart. There was no significant differ-
ence in any of the analyzed variables. Previous studies
[33-35] showed interval progression in atrophy of brain
tissue. For example, annualized rates of atrophy of MSA,
parkinsonian variant, are 1.0% for the whole brain (con-
trols 0.4%) but can be as high as 4.5% in the pons (con-
trols 0.2%) or 3.2% in cerebellum (controls 0.3%). In our
study, the volumes did not change between the pre- and
post-treatment evaluations. However, our imaging com-
parison interval was shorter (8 months versus 1 year).
These findings are also encouraging but need to be vali-
dated in larger studies with longer follow up.Conclusion
Treatment with IVIG appears to be feasible and well tol-
erated. However a larger, placebo-controlled study is
needed to further evaluate a benefit to risk ratio with the
use of IVIG in treatment of MSA.
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